ConductScience.org, home

Paper39006993

Chemo-resistant Gestational Trophoblastic Neoplasia and the Use of Immunotherapy: A Case Report and Review of Literature.

Jacinto EK. Acta Med Philipp, 2024. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Chemo-resistant Gestational Trophoblastic Neoplasia and the Use of Immunotherapy: A Case Report and Review of Literature. Papers, record 39006993. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39006993

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Chemo-resistant Gestational Trophoblastic Neoplasia and the Use of Immunotherapy: A Case Report and Review of Literature.
PubMed
Journal
Acta Med Philipp
PubMed
Year
2024
PubMed
Publication types
Case Reports, Journal Article
PubMed
Citations, by iCite
2
iCite
Relative citation ratio, by iCite
0.43, provisional
iCite
Revised in PubMed
2024-07-16
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Jacinto EKElizabeth K

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References22

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129059432A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer.J Natl Cancer Inst2017https://conductscience.org/library/papers/29059432PubMed
226760424Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia.Cochrane Database Syst Rev2016https://conductscience.org/library/papers/26760424PubMed
332964090Successful treatment of metastatic refractory gestational choriocarcinoma with pembrolizumab: A case for immune checkpoint salvage therapy in trophoblastic tumors.Gynecol Oncol Rep2020https://conductscience.org/library/papers/32964090PubMed
429442540Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.J Clin Oncol2018https://conductscience.org/library/papers/29442540PubMed
525550880Epithelioid trophoblastic tumor after induced abortion with previous broad choriocarcinoma: a case report and review of literature.Int J Clin Exp Pathol2014https://conductscience.org/library/papers/25550880PubMed
632297899Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer.JAMA Oncol2020https://conductscience.org/library/papers/32297899PubMed
733948476Vaginal mucositis related to immunotherapy in endometrial cancer.Gynecol Oncol Rep2021https://conductscience.org/library/papers/33948476PubMed
834145099Predictors of chemotherapy resistance & relapse in gestational trophoblastic neoplasia.Indian J Med Res2020https://conductscience.org/library/papers/34145099PubMed
931569067Effective anti-programmed cell death 1 treatment for chemoresistant gestational trophoblastic neoplasia.Eur J Cancer2019https://conductscience.org/library/papers/31569067PubMed
109826467Risk factors for the prediction of treatment failure in gestational trophoblastic tumors treated with EMA/CO regimen.Gynecol Oncol1998https://conductscience.org/library/papers/9826467PubMed
1133634869Low-dose pembrolizumab in the treatment of advanced non-small cell lung cancer.Int J Cancer2021https://conductscience.org/library/papers/33634869PubMed
1235627534Modified-Dose Pembrolizumab and Prognostic Outcomes among Non-Small Cell Lung Cancer Patients: A Chart Review Study.Int J Environ Res Public Health2022https://conductscience.org/library/papers/35627534PubMed
1332395603A case of multi-agent drug resistant choriocarcinoma treated with Pembrolizumab.Gynecol Oncol Rep2020https://conductscience.org/library/papers/32395603PubMed
1427362903PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases.Int J Gynecol Pathol2017https://conductscience.org/library/papers/27362903PubMed
1525547507Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopause.J Clin Oncol2015https://conductscience.org/library/papers/25547507PubMed
1634258357Long-term survival in multiresistant metastatic choriocarcinoma after pembrolizumab treatment: A case report.Gynecol Oncol Rep2021https://conductscience.org/library/papers/34258357PubMed
1729185430Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia.Lancet2017https://conductscience.org/library/papers/29185430PubMed
1834624252Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial.Lancet Oncol2021https://conductscience.org/library/papers/34624252PubMed
1928742453Complete Serologic Response to Pembrolizumab in a Woman With Chemoresistant Metastatic Choriocarcinoma.J Clin Oncol2017https://conductscience.org/library/papers/28742453PubMed
2028881921Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol2017https://conductscience.org/library/papers/28881921PubMed

See all 22 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
41627371Checkpoint Inhibition in Gestational Trophoblastic Neoplasia: A Narrative Review on the Reawakening of Antitumor Immunity.Adv Ther2026https://conductscience.org/library/papers/41627371PubMed
40323395Clinical routine care for choriocarcinoma: a descriptive analysis of data from the Baden-Wuerttemberg Cancer Registry (BWCR).Arch Gynecol Obstet2025https://conductscience.org/library/papers/40323395PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CGB593659PubTator's text mininghttps://conductscience.org/library/genes/93659

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39006993

GET https://conductscience.org/api/papers/v1/39006993/references?page=2